Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Fladrafinil and Modafiendz — mechanism, dosing, side effects, legal status, and pricing.
Fladrafinil (CRL-40,941) is a non-peptide synthetic eugeroic and the bis(4-fluorophenyl)-substituted analog of adrafinil, retaining adrafinil's N-hydroxyacetamide group. Never approved or marketed as a pharmaceutical in any jurisdiction, it is sold exclusively as an unregulated research chemical. Added to WADA's S6 (Stimulants, non-specified) category on the 2026 Prohibited List, effective 1 January 2026.
Modafiendz is a non-peptide diphenylmethylsulfinylacetamide, specifically an N-methylated, bis(4-fluoro)-ring-substituted analog of modafinil. It is an unapproved research/designer chemical with no marketing authorization in any jurisdiction and no validated human dose. Its closest structural relatives, flmodafinil (CRL-40,940) and fladrafinil (CRL-40,941), are explicitly named as WADA-prohibited S6 stimulants on the 2026 list; Modafiendz itself is not explicitly named but may fall under WADA's generic “similar structure or effect” clause. No human pharmacokinetic, safety, or efficacy studies have been published.
Fladrafinil
Modafiendz
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Fladrafinil
No pricing data yet.
Check Fladrafinil prices →Modafiendz
No pricing data yet.
Check Modafiendz prices →COA corpus from Disclosed Labs — independently tested batches only.
Fladrafinil
2
COAs
99.6%
Avg purity
1
Labs
Modafiendz
2
COAs
99.5%
Avg purity
2
Labs
No clinical trials for any therapeutic indication exist; no FDA approval has been granted. The only identified human data are: (1) a 2026 peer-reviewed pharmacokinetics/metabolism study for anti-doping purposes (Krug et al., Drug Testing and Analysis), which administered fladrafinil orally to healthy volunteers and confirmed metabolism to flmodafinil, flmodafinil acid, and flmodafinil sulfone; and (2) unverified patent-holder claims from 1984 describing oral 50 mg capsules for hypersomnia/psychasthenia with reported 'excellent results' over 2–8 weeks—this is not an independently published or peer-reviewed trial. Animal studies (mice/rats, intraperitoneal, 16–256 mg/kg) from the 1984 Lafon patent reported reduced barbiturate-induced sleep duration, increased spontaneous motor activity, reduced inter-group aggression, improved motor recovery following hypoxic stress, and prolonged amphetamine-induced stereotypy.
No human data exists. No ClinicalTrials.gov record, no DrugBank entry, and no INN was found; NCATS Inxight Drugs classifies it only as “Other (designer drug),” racemic, with no approval year. Only two PubMed-indexed publications reference this compound, both analytical/forensic chemistry papers: one validated an LC-HRMS method to screen dietary supplements for modafinil analogs (adrafinil, not Modafiendz, was confirmed present in tested products), and one analyzed heat-induced thermal degradation during GC-MS (relevant to forensic identification). No preclinical pharmacology, toxicology, or efficacy studies in animals have been published.
Key references
Fladrafinil and Modafiendz are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs